

04-10-2002

RECOR



102049173

Commissioner for Patents: Please record the attached original document(s) or copy(ies).	
1. Name of conveying party(ies): Pharmacia AB Additional name(s) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies): Biovitrum AB SE-112 76 Stockholm Sweden Additional names/addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: Execution Date: 1/2/2002; 2/5/2002	
4. Application number(s) or patent number(s): If this document is being filed with a new application, the execution date of the application is: A. Patent Application No(s): B. Patent No(s): 5,455,227 Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
5. Name/address of party to whom correspondence concerning document should be mailed: JANIS K. FRASER, PH.D., J.D. Fish & Richardson P.C. 225 Franklin Street Boston, Massachusetts 02110-2804	6. Total number of applications/patents involved: 1 7. Total fee (37 CFR §3.41): \$40 <input checked="" type="checkbox"/> Enclosed <input type="checkbox"/> Authorized to charge Deposit Account. 8. Deposit Account No.: 06-1050 Please apply any additional charges, or any credits, to our Deposit Account No. 06-1050.
DO NOT USE THIS SPACE	
9. Statement and Signature: <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>	
Jack Brennan Reg. No. 47,443 Name of Person Signing	 Signature March 22, 2002 Date
Total number of pages including coversheet, attachments and document: 3	

20408496.doc

04/09/2002 LNUELLER 00000068 5455227

01 FC:581

40.00 RP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner of Patents, Washington, D.C. 20231.

March 22, 2002  
Date of Deposit

Signature

Dawn M. Corey

Printed Name of Person Signing Certificate

PATENT  
REEL: 012754 FRAME: 0767

ASSIGNMENT

WHEREAS, Pharmacia AB (formerly named Pharmacia & Upjohn Aktiebolag), a corporation duly organized and existing under the laws of Sweden and having a principal place of business at SE-112 87, Stockholm, Sweden (hereinafter "Assignor"), is the owner of the entire right, title and interest in and to a United States Patent entitled BIOLOGICALLY ACTIVE LIPOPROTEIN AND ITS USE, issued October 3, 1995, and assigned U.S. Patent Number 5,455,227 (hereinafter "Patent");

WHEREAS, Biovitrum AB, a corporation duly organized and existing under the laws of Sweden and having a principal place of business at SE-112 76, Stockholm, Sweden (hereinafter "Assignee"), is desirous of obtaining the entire right, title and interest in and to the Patent;


NOW, THEREFORE, in consideration of one dollar (\$1.00) and other good and valuable considerations paid by Assignee to Assignor, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee, its successors and assignees, the entire right, title and interest in and to the Patent, including the right to sue for past infringement thereof.

This assignment includes the Patent and any and all United States patent applications and patents for any inventions or improvements that are the subject of the Patent.

IN TESTIMONY WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized officers.


Pharmacia AB

Date: 2 January 2002



By: Harald Alm  
Title: Vice President Finance

Date: 2 January 2002



By: Inger Brattne  
Title: Associate General Counsel, Scandinavia


AT

A duly authorized officer of Assignee hereby acknowledges receipt of the entire right, title and interest in and to the Patent.

STOCKHOLM

Date: 2002 -02- 05

Biovitrum AB



By: Fredrik Berg

Title: Vice President, General Counsel

20336288.doc



**Ulf Lindquist**  
VP, Site Management